BridgeBio Pharma, Inc. - Common Stock (BBIO)

CUSIP: 10806X102

Q2 2026 13F Holders as of 30 Jun 2026

Holder snapshot 7 signals
Share change
-1,331,173
Put/Call ratio
17%
SEC-reported price per share
$74.48
Number of holders
475
Value change
-$99,973,754
Number of buys
252
Open additional details 1 more signal available
Number of sells
236
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
193,965,216

Security key

10806X102

Report period

Q2 2026

Institutions

475

Top holders

10

Ownership snapshot

Top reported holders of BBIO - BridgeBio Pharma, Inc. - Common Stock (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Janus Henderson Group Ltd.
Disclosed value leader
BlackRock, Inc.
Comparable rows
5/15
Latest evidence
30 Jun 2026
13F 13D/G 3/4/5 Lead comparable stake: 6.8% 10 rows are not safely comparable across share classes. 13D/G row: Janus Henderson Group Ltd. Showing 1-6 of 15 holder rows.

Quick read

Janus Henderson Group Ltd. leads the comparable SEC ownership view at 6.8%.

5 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Janus Henderson Group Ltd.'s linked filing trail.
Comparable ownership Top 5
Janus Henderson Group Ltd. 6.8%
FARALLON CAPITAL MANAGEMENT, L.L.C. 5.5%
Farallon Capital Partners, L.P. 5.2%
Neil Kumar 4.6%
PRICE T ROWE ASSOCIATES INC /MD/ 1.1%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Janus Henderson Group Ltd.
13F 13D/G
Company · JANUS HENDERSON GROUP PLC
6.8%
Reported 13D/G · 31 Mar 2026
$978,607,712
13,179,013 shares
— 31 Mar 2026
FARALLON CAPITAL MANAGEMENT, L.L.C.
13D/G 13F
Company
5.5%
Reported 13D/G · 30 Jun 2026
$836,992,038
10,743,063 shares
$0 30 Jun 2026
Farallon Capital Partners, L.P.
13D/G
Dapice Joshua J.
5.2%
Reported 13D/G · 22 May 2026
$674,408,855
10,226,063 shares
$0 22 May 2026
Neil Kumar
13D/G
4.6%
Reported 13D/G · 31 Mar 2026
$689,354,243
9,282,982 shares
-$87,903,790 31 Mar 2026
PRICE T ROWE ASSOCIATES INC /MD/
13F 13D/G
Company · T. Rowe Price Associates, Inc.
1.1%
Reported 13D/G · 30 Sep 2025
$286,232,000
4,239,544 shares
mixed-class rows
— 31 Mar 2026
VIKING GLOBAL INVESTORS LP
13F 3/4/5
Company · 10%+ Owner
—
denominator unverified
$879,419,149
11,842,434 shares
— 31 Mar 2026
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q2 2026

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
475
Shares
193,646,489
Rows available
475
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q2 2026 vs Q1 2026 Across Filers

Q1 2026 holders
462
Q2 2026 holders
475
Holder diff
13
Investor Q1 2026 Shares Q2 2026 Shares Share Diff Share Chg % Q1 2026 value Q2 2026 value Value change Value Chg %
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .